CN101007846A - 一种t8合成产物及其用途 - Google Patents
一种t8合成产物及其用途 Download PDFInfo
- Publication number
- CN101007846A CN101007846A CN 200610002073 CN200610002073A CN101007846A CN 101007846 A CN101007846 A CN 101007846A CN 200610002073 CN200610002073 CN 200610002073 CN 200610002073 A CN200610002073 A CN 200610002073A CN 101007846 A CN101007846 A CN 101007846A
- Authority
- CN
- China
- Prior art keywords
- lys
- branch
- functional
- thr
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 48
- 229920001184 polypeptide Polymers 0.000 claims abstract description 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 17
- 150000001413 amino acids Chemical class 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 208000015181 infectious disease Diseases 0.000 claims abstract description 3
- 102000007079 Peptide Fragments Human genes 0.000 claims description 17
- 108010033276 Peptide Fragments Proteins 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 238000003786 synthesis reaction Methods 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 230000002924 anti-infective effect Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 5
- 230000036039 immunity Effects 0.000 claims description 4
- 229960001438 immunostimulant agent Drugs 0.000 claims description 4
- 239000003022 immunostimulating agent Substances 0.000 claims description 4
- 230000003308 immunostimulating effect Effects 0.000 claims description 4
- 101001057305 Homo sapiens Microtubule-associated protein 1S Proteins 0.000 claims description 3
- 102100027228 Microtubule-associated protein 1S Human genes 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 229940126701 oral medication Drugs 0.000 claims 1
- 239000000047 product Substances 0.000 description 29
- 239000003708 ampul Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 230000000118 anti-neoplastic effect Effects 0.000 description 4
- 239000013256 coordination polymer Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 230000003335 steric effect Effects 0.000 description 3
- 238000011146 sterile filtration Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000019846 buffering salt Nutrition 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
原辅料 | 用量 |
合成产物甘露醇磷酸二氢钠(NaH2PO4·2H2O)磷酸氢二钠(Na2HPO4·12H2O)注射用水加至 | 1g50g0.796g1.755g1000ml |
共制成 | 1000瓶 |
原辅料 | 质量规格 | 来源 | 用途 |
合成产物甘露醇磷酸二氢钠磷酸氢二钠注射用水针用活性炭 | 符合暂定标准CP.2000 89页CP.2000 1058页GB1263-86CP.2000 428页CP.2000 465页 | 自制北京制药厂苏州中化药品有限公司苏州中化药品有限公司北京制药厂北京大力活性炭厂 | 主药支撑剂缓冲盐缓冲盐溶剂吸附剂 |
包装规格:成品为白色冻干粉针,1mg/安瓿,10安瓿/盒 | |||
储存:2-8℃避光保存,有效期3年。 |
原辅料 | 用量 |
合成产物注射用水加至 | 1g1000ml |
共制成 | 1000瓶 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200610002073 CN101007846A (zh) | 2006-01-24 | 2006-01-24 | 一种t8合成产物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200610002073 CN101007846A (zh) | 2006-01-24 | 2006-01-24 | 一种t8合成产物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101007846A true CN101007846A (zh) | 2007-08-01 |
Family
ID=38696536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200610002073 Pending CN101007846A (zh) | 2006-01-24 | 2006-01-24 | 一种t8合成产物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101007846A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011079817A1 (zh) * | 2009-12-31 | 2011-07-07 | 中国疾病预防控制中心病毒病预防控制所 | Tuftsin和流感基质蛋白的树状聚合物及其应用 |
CN105504070A (zh) * | 2016-01-29 | 2016-04-20 | 深圳市中美康士生物科技有限公司 | 一种四分支多肽及其应用 |
CN107224582A (zh) * | 2016-03-24 | 2017-10-03 | 韩震 | 免疫增强肽在制备通过粘膜给药的增强免疫功能药物中的应用 |
CN108196073A (zh) * | 2018-03-13 | 2018-06-22 | 江苏浩欧博生物医药股份有限公司 | 一种测定抗环瓜氨酸肽抗体的试剂盒及其应用 |
-
2006
- 2006-01-24 CN CN 200610002073 patent/CN101007846A/zh active Pending
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011079817A1 (zh) * | 2009-12-31 | 2011-07-07 | 中国疾病预防控制中心病毒病预防控制所 | Tuftsin和流感基质蛋白的树状聚合物及其应用 |
CN102153654A (zh) * | 2009-12-31 | 2011-08-17 | 中国疾病预防控制中心病毒病预防控制所 | 以免疫活性肽为载体的分支多肽及其衍生物与应用 |
CN102153654B (zh) * | 2009-12-31 | 2012-10-10 | 中国疾病预防控制中心病毒病预防控制所 | 以免疫活性肽为载体的分支多肽及其衍生物与应用 |
CN105504070A (zh) * | 2016-01-29 | 2016-04-20 | 深圳市中美康士生物科技有限公司 | 一种四分支多肽及其应用 |
CN105504070B (zh) * | 2016-01-29 | 2019-04-12 | 深圳市中美康士生物科技有限公司 | 一种四分支多肽及其应用 |
CN107224582A (zh) * | 2016-03-24 | 2017-10-03 | 韩震 | 免疫增强肽在制备通过粘膜给药的增强免疫功能药物中的应用 |
CN108196073A (zh) * | 2018-03-13 | 2018-06-22 | 江苏浩欧博生物医药股份有限公司 | 一种测定抗环瓜氨酸肽抗体的试剂盒及其应用 |
CN108196073B (zh) * | 2018-03-13 | 2019-09-13 | 江苏浩欧博生物医药股份有限公司 | 一种测定抗环瓜氨酸肽抗体的试剂盒及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100503634C (zh) | 一种t4合成产物及其用途 | |
CN102793032A (zh) | 一种养生菌茶及其应用 | |
CN103547279A (zh) | 细胞毒性二肽的冻干制剂 | |
CN103462911B (zh) | 一种冻干粉针剂的制备技术 | |
CN102351844B (zh) | 泮托拉唑钠化合物及其药物组合物 | |
CN101007846A (zh) | 一种t8合成产物及其用途 | |
EP1723855B1 (en) | Hydrogels containing gamma-polyglutamic acid (gamma-PGA, H Form) and gamma-polyglutamates for use as nutrition supplements in dietary products | |
CN101856335B (zh) | 注射用阿奇霉素组合物冻干粉针 | |
US20040121949A1 (en) | Composition comprising partly-hydrolysed fish gelatin and a method for treatment of a patient suffering from arthrosis, osteoporosis and other diseases | |
CN102813632A (zh) | 一种稳定的胸腺法新制剂及其制备方法 | |
CN102018720B (zh) | 一种复合维生素冻干粉针剂的制备方法 | |
CN101732263A (zh) | 磷酸肌酸钠冻干制剂及其制备方法 | |
JP5927191B2 (ja) | 全卵タンパク質ペプチド、その調製方法及び使用 | |
CN102429864A (zh) | 一种脂溶性维生素注射液(ii)和注射用水溶性维生素的药物组合物及其制法 | |
CN100525758C (zh) | 藤黄酸脂质体及其冻干粉针剂与制备方法 | |
CN101198350A (zh) | 含胃动素样肽的稳定的缓冲的药物组合物 | |
CN102247373A (zh) | 一种甲硫氨酸维b1化合物的组合物 | |
CN107519136A (zh) | 一种氯化琥珀胆碱冻干制剂及其制备方法 | |
CN102367229B (zh) | 一种二乙酰氨乙酸乙二胺化合物及其药物组合物 | |
CN103505424B (zh) | 一种注射用硼替佐米的制备方法 | |
CN1732934B (zh) | 注射用盐酸倍他司汀冻干粉针剂及其制备方法 | |
CN102499939A (zh) | 一种注射用脂溶性维生素和注射用水溶性维生素的药物组合物及其制法 | |
CN107216369A (zh) | 一种鱼精蛋白类似活性肽及其制备方法与应用 | |
CN102670528A (zh) | 注射用泮托拉唑钠冻干粉组合物及其制备方法 | |
CN1977967A (zh) | 一种注射针剂的制备及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING ZHONGTIAN KANGTAI BIOLOGY TECHNOLOGY CO., Free format text: FORMER OWNER: HAN SU Effective date: 20080704 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080704 Address after: Room 807, design building, No. 8, Fu Xin East Street, Beijing, Chaoyang District, China: 100029 Applicant after: Beijing Zhongtian Kangtai Bio-Tech Co., Ltd. Address before: Beijing City, Haidian District Institute of Road D China University of Mining and Technology No. 11 East two building 1-302 No. 100083 post encoding: Applicant before: Han Su |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090320 Address after: Room 807, design building, No. 8, Fu Xin East Street, Beijing, Chaoyang District, China: 100029 Applicant after: Beijing Zhongtian Kangtai biological science and Technology Co., Ltd. Co-applicant after: Beijing Yuansen Kangtai Pharmaceutical Research Co., Ltd. Address before: Room 807, design building, No. 8, Fu Xin East Street, Beijing, Chaoyang District, China: 100029 Applicant before: Beijing Zhongtian Kangtai Bio-Tech Co., Ltd. |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |